Ny Sin

3.0k citations

31 papers · 2.7k · 1 hit paper · h-index 20

Impact in

Oncology top 5%
- Peptidase Inhibition and Analysis
Virology top 5%

Papers in

Infectious Diseases 13
- HIV/AIDS drug development and treatment 12
Virology 7
- HIV Research and Treatment 7

Co-authors: Craig M. Crews (7 shared papers)Lihao Meng (5 shared papers)Benjamin H. B. Kwok (3 shared papers)Mikael Elofsson (2 shared papers)Royce Mohan (1 shared paper)James Wen (1 shared paper)William G. Bornmann (1 shared paper)Kyung Bo Kim (2 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (7 papers)Journal of Medicinal Chemistry (5 papers)Antimicrobial Agents and Chemotherapy (3 papers)ACS Medicinal Chemistry Letters (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States Germany India

In The Last Decade

Ny Sin

31 papers receiving 2.5k citations

Ny Sin's Hit Papers

align trajectories log scale

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity 1999 · 835 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

1999 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Ny Sin

Since Specialization

Citations

This map shows the geographic impact of Ny Sin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ny Sin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ny Sin more than expected).

Fields of papers citing papers by Ny Sin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ny Sin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ny Sin. The network helps show where Ny Sin may publish in the future.

Co-authors

The 25 scholars most cited alongside Ny Sin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ny Sin Line = papers co-authored together Ny Sin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity Proceedings of the National Academy of Sciences ·Lihao Meng, Royce Mohan, Benjamin H. B. Kwok, Mikael Elofsson, Ny Sin, Craig M. Crews Hit paper breakdown →	1999	835
2	The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 Proceedings of the National Academy of Sciences ·Ny Sin, Lihao Meng, Margaret Q. W. Wang, James Wen, William G. Bornmann, Craig M. Crews	1997	566
3	Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology Bioorganic & Medicinal Chemistry Letters ·Ny Sin, Kyung Bo Kim, Mikael Elofsson, Lihao Meng, Hak Auth, Benjamin H. B. Kwok, Craig M. Crews	1999	174
4	Eponemycin exerts its antitumor effect through the inhibition of proteasome function. PubMed ·Lin Meng, Benjamin H. B. Kwok, Ny Sin, Craig M. Crews	1999	140
5	Orally Active Fusion Inhibitor of Respiratory Syncytial Virus Antimicrobial Agents and Chemotherapy ·Christopher Cianci, Kuo‐Long Yu, Keith D. Combrink, Ny Sin, Bradley C. Pearce, Alan Wang, Rita L. Civiello, Stacey Voss	2004	119
6	Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency Bioorganic & Medicinal Chemistry Letters ·Kyung Bo Kim, Jayhyuk Myung, Ny Sin, Craig M. Crews	1999	108
7	The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection Journal of Medicinal Chemistry ·Paul M. Scola, Li‐Qiang Sun, Alan Xiangdong Wang, Jie Chen, Ny Sin, Brian L. Venables, Sing‐Yuen Sit, Yan Chen	2014	98
8	Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection Antimicrobial Agents and Chemotherapy ·Christopher Cianci, Eugene V. Genovesi, Lucinda M. Lamb, Ivette Medina, Zheng Yang, Lisa M. Zadjura, Hyekyung Yang, Celia J D’Arienzo	2004	70
9	Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability Bioorganic & Medicinal Chemistry Letters ·Kuo‐Long Yu, Ny Sin, Rita L. Civiello, X. Alan Wang, Keith D. Combrink, H. Belgin Gülgeze, Brian L. Venables, Jordan J Wright	2006	61
10	Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection Journal of Medicinal Chemistry ·Paul M. Scola, Alan Xiangdong Wang, Andrew C. Good, Li‐Qiang Sun, Keith D. Combrink, Jeffrey A. Campbell, Jie Chen, Yong Qiang Tu	2014	58
11	Eponemycin analogues: syntheses and use as probes of angiogenesis Bioorganic & Medicinal Chemistry ·Ny Sin, Lihao Meng, Hak Auth, Craig M. Crews	1998	57
12	Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage Antimicrobial Agents and Chemotherapy ·Beata Nowicka-Sans, Tricia Protack, Zeyu Lin, Zhufang Li, Sharon Zhang, Yongnian Sun, Himadri K. Samanta, Brian Terry	2016	56
13	Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity ACS Medicinal Chemistry Letters ·Alicia Regueiro‐Ren, Zheng Liu, Yan Chen, Ny Sin, Sing‐Yuen Sit, Jacob J. Swidorski, Jie Chen, Brian L. Venables	2016	49
14	Respiratory syncytial virus fusion inhibitors. Part 7: Structure–activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo Bioorganic & Medicinal Chemistry Letters ·Ny Sin, Brian L. Venables, Keith D. Combrink, H. Belgin Gülgeze, Kuo‐Long Yu, Rita L. Civiello, Jan Willem Thuring, X. Alan Wang	2009	37
15	The Antiproliferative Agent Didemnin B Uncompetitively Inhibits Palmitoyl Protein Thioesterase Biochemistry ·Lihao Meng, Ny Sin, Craig M. Crews	1998	36
16	Inhibitors of HIV-1 maturation: Development of structure–activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids Bioorganic & Medicinal Chemistry Letters ·Jacob J. Swidorski, Zheng Liu, Sing‐Yuen Sit, Jie Chen, Yan Chen, Ny Sin, Brian L. Venables, Dawn DiGiugno Parker	2016	32
17	Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176) Journal of Medicinal Chemistry ·Alicia Regueiro‐Ren, Jacob J. Swidorski, Zheng Liu, Yan Chen, Ny Sin, Sing‐Yuen Sit, Jie Chen, Brian L. Venables	2018	27
18	Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing Journal of Medicinal Chemistry ·Li‐Qiang Sun, Eric S. Mull, Barbara Zhizhen Zheng, Stanley V. D’Andrea, Qian Zhao, Alan Xiangdong Wang, Ny Sin, Brian L. Venables	2016	26
19	The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation Bioorganic & Medicinal Chemistry Letters ·Yan Chen, Sing‐Yuen Sit, Jie Chen, Jacob J. Swidorski, Zheng Liu, Ny Sin, Brian L. Venables, Dawn DiGiugno Parker	2018	20
20	The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation Journal of Medicinal Chemistry ·Alicia Regueiro‐Ren, Sing‐Yuen Sit, Yan Chen, Jie Chen, Jacob J. Swidorski, Zheng Liu, Brian L. Venables, Ny Sin	2022	20

About Ny Sin

Ny Sin is a scholar working on Infectious Diseases, Virology, Hepatology, Organic Chemistry and Oncology, having authored 31 papers that have together received 2.7k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (7 papers), Peptidase Inhibition and Analysis (6 papers), Hepatitis C virus research (6 papers), Respiratory viral infections research (4 papers), Biochemical and Molecular Research (4 papers), Ubiquitin and proteasome pathways (4 papers) and Virology and Viral Diseases (3 papers). The work is most often cited by research in Oncology (768 citations), Virology (135 citations), Molecular Biology (1.7k citations), Hepatology (134 citations) and Infectious Diseases (311 citations). Ny Sin has collaborated with scholars based in United States, Germany and India. Frequent co-authors include Craig M. Crews, Lihao Meng, Benjamin H. B. Kwok, Mikael Elofsson, Royce Mohan, James Wen, William G. Bornmann, Kyung Bo Kim, Lin Meng and Jayhyuk Myung. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy, ACS Medicinal Chemistry Letters and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ny Sin

Impact in

Papers in i

In The Last Decade

Ny Sin

Ny Sin's Hit Papers

Peers

Countries citing papers authored by Ny Sin

Fields of papers citing papers by Ny Sin

All Works

About Ny Sin

Explore authors with similar magnitude of impact

Papers in